Gaetan de Schaetzen

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

A. Hauschild, P. Ascierto, R. Dummer, 2016, The New England journal of medicine.

Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.

R. Dummer, A. Eggermont, A. Testori, 2016, European Journal of Cancer.

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.

D. Schadendorf, R. Dummer, A. Testori, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

P. Ascierto, R. Dummer, J. Wolchok, 2015, The Lancet. Oncology.

Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy

M. Buyse, J. Kirkwood, A. Eggermont, 2018, Journal of the National Cancer Institute.

Socio‐economic outcomes among long‐term childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC CLG studies: Results of the 58LAE study

P. Rohrlich, G. Rossi, J. van der Werff Ten Bosch, 2022, European journal of cancer care.